logo-loader
viewMaxCyte Inc

MaxCyte says outlook is "exceptionally positive" after stellar year

“MaxCyte is well-positioned in the rapidly growing, global gene editing and cell therapy space," said CEO Doug Doerfler

MaxCyte Inc -

MaxCyte Inc’s (LON:MXCT) shares rose on Monday after chief executive Doug Doerfler said the life sciences group’s outlook for the current year and beyond was “exceptionally positive” after its full-year revenues exceeded market expectations.

In morning trading, MaxCyte shares were 9% higher at 132.50p.

READ:MaxCyte inks new development and commercialization agreement with KSQ Therapeutics

The company is at the cutting edge of cell-therapy and immuno-oncology, with commercial deals worth more than US$650mln in milestone payments.

However, it generates its income from licensing out its CARMA technology to most of the world’s largest drug companies and it also has an instruments and disposables business.

Last year, MaxCyte generated sales of US$21.6mln, up 30% year-on-year. It had cash and equivalents at the end of 2019 of US$16.7m.

Running in parallel to its commercial activities, MaxCyte has a drug discovery operation.

It is currently overseeing the phase I clinical trial of MCY-M11 that is been administered to women with hard to treat ovarian cancer and people with peritoneal mesothelioma (which affects the lining of the abdomen).

In this latest update, MaxCyte said there had been no dose-limiting toxicities or side-effects from the drug, which is a mesothelin-targeting chimeric antigen receptor (CAR) therapy.

So-called CAR-T immunotherapies use specially altered T cells — a part of the immune system — to fight cancer.

Great strides in the clinic

“We have made great strides in the clinic and have seen continued good progress with our phase I clinical trial with MCY-M11,” said CEO Doerfler.

Assessing the performance of the wider group, he added: “MaxCyte is well-positioned in the rapidly growing, global gene editing and cell therapy space. 

“We have continued to make impressive progress across all areas of the business and our outlook is exceptionally positive. 

“Our financial performance is strong, reflecting the high demand for our instruments and disposables business as well as robust revenue generation from an ever-increasing number of commercial licenses.

“Notably, we entered one commercial agreement in 2017, two in 2018, and five in 2019 and continue to be selected as the partner of choice by leading gene editing cell therapy developers, globally.”

Quick facts: MaxCyte Inc

Price: 159.9 GBX

AIM:MXCT
Market: AIM
Market Cap: £91.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte in 'exceptional position to benefit from explosive growth in gene...

Proactive Research analyst Emma Ulker gives her take on the recent trading update from MaxCyte (LON:MXCT). The firm signed five of eight clinical/commercial deals for its proprietary cell engineering Flow Electroporation technology in FY19. Ulker says the increasing momentum in deal flow...

3 weeks ago

2 min read